UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2017 to Q4 2025

Type / Class
Equity / Ordinary Shares, par value NIS 0.01 per share
Symbol
URGN on Nasdaq
Shares outstanding
46,239,275
Price per share
$23.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
43,904,776
Total reported value
$877,180,389
% of total 13F portfolios
0%
Share change
+3,965,263
Value change
+$94,298,888
Number of holders
158
Price from insider filings
$23.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Paradigm Biocapital Advisors LP 9% +80% $84,110,876 +$37,586,159 4,216,084 +81% Paradigm BioCapital Advisors LP 30 Sep 2025
TORONTO DOMINION BANK 6.9% $63,650,674 3,190,510 The Toronto-Dominion Bank 30 Sep 2025
MORGAN STANLEY 5.4% +180% $35,433,378 +$24,712,637 2,488,299 +231% Morgan Stanley 30 Jun 2025
MENORA MIVTACHIM HOLDINGS LTD. 5% $24,780,614 2,303,031 Menora Mivtachim Holdings Ltd 11 Mar 2025
BlackRock, Inc. 5% $31,292,937 2,284,206 BlackRock, Inc. 30 Jun 2025
Soleus Capital Master Fund, L.P. 4.7% -6% $31,114,400 -$1,993,600 2,185,000 -6% Soleus Capital Master Fund, L.P. 30 Jun 2025
Adage Capital Management, L.P. 2.8% -60% $13,740,520 -$17,765,685 1,277,000 -56% Adage Capital Management, L.P. 31 Mar 2025
Monograph Capital Holdings Advisors, LLC 1.8% $8,503,556 838,615 Monograph Capital Partners I, L.P. 05 Jun 2025

As of 30 Sep 2025, 158 institutional investors reported holding 43,904,776 shares of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN). This represents 95% of the company’s total 46,239,275 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) together control 76% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 9.8% 4,543,895 0% 1.1% $90,650,705
Paradigm Biocapital Advisors LP 9.1% 4,216,084 2.5% $84,110,876
TORONTO DOMINION BANK 6.9% 3,190,510 0% 0.12% $63,650,675
BlackRock, Inc. 5.6% 2,581,286 +7.3% 0% $51,496,656
MORGAN STANLEY 5.5% 2,528,446 +2% 0% $50,442,497
Jefferies Financial Group Inc. 4.8% 2,199,652 0% 0.4% $43,883,057
SILVERARC CAPITAL MANAGEMENT, LLC 3.4% 1,577,283 -22% 4.6% $31,466,796
MILLENNIUM MANAGEMENT LLC 3.2% 1,468,737 +147% 0.02% $29,301,303
ACORN CAPITAL ADVISORS, LLC 2.7% 1,259,749 0% 13% $25,131,993
SG Americas Securities, LLC 2.5% 1,157,383 +0.72% 0.08% $23,090,000
MENORA MIVTACHIM HOLDINGS LTD. 2.5% 1,152,531 0% 0.12% $22,992,993
TANG CAPITAL MANAGEMENT LLC 2.2% 1,000,000 0% 0.77% $19,950,000
D. E. Shaw & Co., Inc. 1.9% 888,933 +3140% 0.01% $17,734,213
STATE STREET CORP 1.8% 819,446 +1.5% 0% $16,347,948
Migdal Insurance & Financial Holdings Ltd. 1.7% 770,909 0% 0.17% $15,380,000
TCG Crossover Management, LLC 1.6% 717,347 0.7% $14,311,073
ORBIMED ADVISORS LLC 1.5% 689,000 +44% 0.33% $13,745,550
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.5% 687,475 0.05% $13,715,126
Soleus Capital Management, L.P. 1.5% 679,000 -69% 0.72% $13,546,050
CITADEL ADVISORS LLC 1.3% 602,277 +11% 0.01% $12,015,426
Boxer Capital Management, LLC 1.2% 575,000 0% 3.7% $11,471,250
JPMORGAN CHASE & CO 1.2% 534,545 +37% 0% $10,664,172
Nuveen, LLC 1.1% 507,531 +510% 0% $10,125,244
GEODE CAPITAL MANAGEMENT, LLC 1% 471,229 +0.11% 0% $9,401,017
GOLDMAN SACHS GROUP INC 0.92% 424,916 +46% 0% $8,477,074

Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,539,939 $36,064,879 +$7,423,663 $23.42 4
2025 Q3 43,904,776 $877,180,389 +$94,298,888 $19.95 158
2025 Q2 39,798,464 $545,161,051 +$3,475,596 $13.70 149
2025 Q1 41,643,932 $460,619,197 +$59,835,372 $11.06 139
2024 Q4 36,306,231 $386,611,717 -$9,614,830 $10.65 139
2024 Q3 35,097,143 $445,735,362 -$58,506,168 $12.70 127
2024 Q2 38,225,503 $641,423,803 +$207,327,873 $16.78 114
2024 Q1 27,162,024 $407,381,837 +$84,866,378 $15.00 111
2023 Q4 21,390,291 $320,854,510 +$51,912,609 $15.00 103
2023 Q3 17,724,118 $248,330,352 +$65,704,038 $14.01 100
2023 Q2 13,209,673 $136,728,106 +$7,180,182 $10.35 84
2023 Q1 12,428,895 $114,822,764 -$4,446,429 $9.24 64
2022 Q4 13,022,042 $115,449,037 -$2,381,858 $8.87 63
2022 Q3 13,319,758 $110,811,074 -$981,981 $8.32 56
2022 Q2 13,444,839 $109,243,080 -$6,040,297 $8.19 60
2022 Q1 14,223,995 $123,920,902 +$1,868,931 $8.71 82
2021 Q4 14,650,914 $139,360,752 +$2,176,410 $9.51 71
2021 Q3 14,085,432 $236,906,894 +$1,235,828 $16.82 88
2021 Q2 13,993,075 $213,691,867 -$5,527,357 $15.27 78
2021 Q1 14,299,652 $278,497,797 -$4,203,728 $19.48 88
2020 Q4 14,549,849 $261,548,580 -$10,506,654 $18.02 81
2020 Q3 15,009,007 $288,527,801 +$6,244,867 $19.29 78
2020 Q2 14,672,947 $381,998,824 +$28,263,022 $26.12 83
2020 Q1 13,991,634 $249,248,555 -$10,038,151 $17.84 78
2019 Q4 14,182,815 $472,998,729 +$4,841,998 $33.37 85
2019 Q3 14,565,725 $346,785,326 -$26,211,624 $23.83 83
2019 Q2 14,681,109 $527,197,234 +$43,911,794 $35.94 84
2019 Q1 13,462,231 $497,232,334 +$142,583,669 $36.94 73
2018 Q4 9,585,700 $412,953,000 +$18,631,256 $43.06 63
2018 Q3 9,922,967 $468,843,000 +$14,656,634 $47.23 70
2018 Q2 9,602,369 $482,439,000 +$24,129,548 $49.76 60
2018 Q1 9,137,601 $454,036,000 +$118,577,913 $49.69 43
2017 Q4 5,741,200 $213,691,000 +$83,149,343 $37.21 40
2017 Q3 3,121,706 $98,400,000 +$1,688,330 $31.52 29
2017 Q2 4,717,310 $85,197,000 +$85,197,000 $18.06 21